CIK 0000875045 · Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330112644
- Phone
- 6176792000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-09 | Freire Maria C Director | Grant or award | +2,005 | 8,820 | ||
| 2026-05-01 | Keeney Adam Head of Corporate Development | Option exercise | +939 | 6,820 | ||
| 2026-05-01 | Keeney Adam Head of Corporate Development | Shares withheld for taxes | −455 | $187.06 | $85K | 6,365 |
| 2026-05-01 | Keeney Adam Head of Corporate Development | Option exercise · Restricted Stock Unit | −939 | 0 | ||
| 2026-04-01 | Godbout Sean Chief Accounting Officer | Option exercise | +181 | 1,395.67 | ||
| 2026-04-01 | Godbout Sean Chief Accounting Officer | Shares withheld for taxes | −54 | $183.78 | $10K | 1,341.67 |
| 2026-04-01 | Godbout Sean Chief Accounting Officer | Option exercise · Restricted Stock Unit | −181 | 364 | ||
| 2026-02-13 | Viehbacher Christopher President and CEO | Grant or award · Restricted Stock Unit | +38,015 | 38,015 | ||
| 2026-02-13 | Singhal Priya Head of Development | Grant or award · Restricted Stock Unit | +10,560 | 10,560 | ||
| 2026-02-13 | Murphy Nicole Head of Pharm Ops and Tech | Grant or award · Restricted Stock Unit | +10,560 | 10,560 | ||
| 2026-02-13 | Kramer Robin Chief Financial Officer | Grant or award · Restricted Stock Unit | +8,450 | 8,450 | ||
| 2026-02-13 | Keeney Adam Head of Corporate Development | Grant or award · Restricted Stock Unit | +8,025 | 8,025 | ||
| 2026-02-13 | Izzar Rachid Head of Global Product Strat. | Grant or award · Restricted Stock Unit | +7,390 | 7,390 | ||
| 2026-02-13 | Grogan Jane Head of Research | Grant or award · Restricted Stock Unit | +8,450 | 8,450 | ||
| 2026-02-13 | Gregory Ginger EVP, Human Resources | Grant or award · Restricted Stock Unit | +8,025 | 8,025 | ||
| 2026-02-13 | Godbout Sean Chief Accounting Officer | Grant or award · Restricted Stock Unit | +1,800 | 1,800 | ||
| 2026-02-13 | ALEXANDER SUSAN H EVP Chief Legal Officer | Grant or award · Restricted Stock Unit | +8,450 | 8,450 | ||
| 2026-02-12 | Murphy Nicole Head of Pharm Ops and Tech | Purchase | +3 | $195.04 | $585 | 19,611.04 |
| 2026-02-09 | Singhal Priya Head of Development | Sale 10b5-1 | −2,660 | $199.83 | $532K | 8,043.14 |
| 2026-02-06 | Viehbacher Christopher President and CEO | Option exercise | +9,008 | 25,451 |
Page 2 of 29 · 579 trades